Opening Asia for Russia

Chinese mRNA vaccine successfully passes clinical trials

29.01.2022 124 просмотров

Chinese mRNA covid vaccine found effective in early trials.


China's first coronavirus vaccine based on messenger ribonucleic acid (mRNA) technology was found to be safe, effective and well tolerated in early clinical trials. This was reported by the Shenzhen Daily newspaper on Friday, citing a report published in the medical scientific journal Lancet Microbe.

This is a vaccine called ARCoV. The principle of its action is similar to the Western drugs Pfizer - BioNTech and Moderna. The novelty was developed by Abogen Biosciences  and Walvax Biotechnology in cooperation with the Academy of Military Sciences of the People's Liberation Army of China.

Testing of the drug took place in a hospital in Hangzhou (eastern Zhejiang province) from October 30 to December 2 last year. The studies involved 120 people aged 18 to 59 years.

The vaccination procedure included two injections, while doctors evaluated five types of doses: 5, 10, 15, 20 and 25 micrograms. It was found that doses of 15 mcg induced the highest titers of neutralizing antibodies, twice as high as in recovering patients from COVID-19.

During the 56 days after the experiments, no serious side effects were recorded. Phase 3 clinical trials are currently underway with a large number of participants.

Mass production of the drug is planned at a facility in the southwestern province of Yunnan, which is specially built by Walvax Biotechnology. At the initial stage, it is planned to produce about 120 million doses per year there.

Новости партнёров